Pharmaceutical products that are pirated, counterfeited, or unregistered can be easily found in the Indonesian market, and pose serious health threats to the public. The annual turnover of counterfeit drugs is estimated to be worth 10% of the total market (around US$200M).
With the turbulent economic and political conditions impacting Indonesia, as well as the lack of coordination amongst the authorities, only little efforts have been demonstrated. The Badan POM (BPOM), the Indonesian regulatory authority, has initiated some actions. The efforts, however, are still inadequate as the prevailing laws and regulations impose only light penalties to the violators, resulting in no deterrence effect. For example, convicted counterfeiters would usually be sentenced to 6 months of imprisonment. The Indonesian Society for Anti-Counterfeiting (MIAP), the EU, and the Institute for Economic and Social Research at the Faculty of Economics of University of Indonesia (LPEM-UI) in their recent joint study recommended the government to show more commitment to tackling the counterfeit medicines problems.
Inadequate law enforcement and increasing trend of drugs counterfeiting remain major challenges for IPMG. Counterfeit medicines are also an issue for many other countries, and IPMG remains optimistic about the prospects of partnership with the government and concerned agencies to address these problems through transparent and harmonious efforts as well as consultative working relationships.